Currently, research on PKMYT1 inhibitors is limited, with lunresertib being the only reported effective PKMYT1 inhibitor, capable of inducing synthetic lethality in cancers with CCND1 amplification [43, 65]. This evidence concerns the gene CCND1 and cancer.